GBM at this stage hard to commercialize due to CAR-T delivery difficulties injection right into the tumour..
This could be part of the reason (in addition to the pending CR at a low price) that the SP stays down, I remember Tony Locantro talking about the GBM treatment when the SP was about 25 cents, a lot of investors got in because of that & now it is delayed.. IMO
Will wait until they sort out the CR just to be safe before adding any more.
Webinar 17/06/24, page-17
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
